See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12 Tips for Traveling With Diabetes
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
DHTV
Popular
Top Rated

Related Medications Videos on Diabetes Health TV

ReliOn at Wal-Mart

Bob Guest

ReliOn at Wal-Mart

Multi-Talented Diabetes Educator Is a Joy to the World

Joy Pape, RN, BSN, CDE, WOCN, CFCN

Multi-Talented Diabetes Educator Is a Joy to the World

The World's First Diabetes Emergency Kit

Gillian Miller - Diabetes and More

The World's First Diabetes Emergency Kit

Diabetes Health Reference Charts
Type 2 Medications Archives

Type 2 Diabetes Medications

Page 2
Sitagliptin (Januvia) Lowers Blood Sugar in People With Type 1 Diabetes

Sitagliptin (Januvia) has long been used to reduce blood sugar in people with type 2 diabetes, but a new study indicates that it can do the same for those with type 1 diabetes. Sitagliptin is a DPP-4 inhibitor; that is, it inhibits, or temporarily prevents, the enzyme DPP-4 from destroying a helpful hormone called GLP-1. GLP-1, which is released by the gut when food arrives there from the stomach, lowers blood sugar by causing the release of insulin, reducing the secretion of glucagon, and slowing stomach emptying and nutrient absorption.

Comments 3 comments - Jan 7, 2011 - * * * * *

FDA Significantly Restricts Access to the Diabetes Drug Avandia

The U.S. Food and Drug Administration today announced that it will significantly restrict the use of the diabetes drug Avandia (rosiglitazone) to patients with Type 2 diabetes who cannot control their diabetes on other medications. These new restrictions are in response to data that suggest an elevated risk of cardiovascular events, such as heart attack and stroke, in patients treated with Avandia.

Comments 0 comments - Sep 23, 2010 - * * * * *

'Sugar Crush' (Diabetes Dietary Supplement) Clinical Research Presented at the 37th Annual AADE Meeting

NaturEra, (http://www.NaturEra.com) a dietary supplements emerging leader, this month announced the launch of its new Sugar Crush dietary supplements would take place at the American Association of Diabetes Educators meeting in San Antonio, Texas.  Sugar Crush research has been accepted for Poster presentation at the AADE meeting.  The full clinical research study (http://www.naturera.com/Manuscript.pdf) shows that NaturEra's 'Sugar Crush' and 'Sugar Crush Daily' dietary supplement formulas used in combination lower and maintain healthy blood sugar levels for people with diabetes. 

Comments 1 comment - Aug 26, 2010 - * * * * *

Victoza® Achieved Improved Blood Sugar Control in African-Americans With Type 2 Diabetes

Novo Nordisk presented results demonstrating that once-daily Victoza® (liraglutide [rDNA] injection) achieved significantly greater improvements in blood sugar control compared to placebo among African-American patients with type 2 diabetes. The meta-analysis of phase 3 data from the Liraglutide Effect and Action in Diabetes (LEAD) trials were presented at the 2010 National Medical Association Annual Convention & Scientific Assembly.

Comments 0 comments - Aug 5, 2010 - * * * * *

FDA Freezes Long-Term Study on Diabetes Drug Avandia

A long-term study on the safety of a popular diabetes drug was put on hold Wednesday by the Food and Drug Administration, while the FDA considers whether it's too dangerous to continue.  Several large studies have linked the drug, Avandia, to a higher risk of heart attacks and other heart problems. While other studies have not found the same risk, last week an FDA advisory panel recommended that the drug not be sold without a stronger warning label or possibly limits on who could receive it.

Comments 0 comments - Jul 23, 2010 - * * * * *

Avandia and the FDA Panel: Scientific Leaders Urge Diabetes Patients to Talk with their Doctor before Making Changes to their Medication Use

The U.S. Food and Drug Administration's (FDA) Joint Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee has completed their evaluation of the scientific research available on the safety of rosiglitazone. The deliberations of the panel reflected the complexity of the issues, with several members voting to add additional warnings or to withdraw the drug from the U.S. market. Ultimately, the final recommendation was to allow Avandia to remain on the market. Now that the expert panel has concluded its meeting, the FDA will review their recommendations and make the final decision on whether the drug remains available to patients.

Comments 0 comments - Jul 15, 2010 - * * * * *

Intensive BG Control and the Onset of Organ Damage in Type 2s

Data from the massive ACCORD study on intensive blood sugar control shows that lowering blood sugar levels in people with longstanding type 2 diabetes to near-normal may delay the appearance of signs that point to damage to nerves, eyes, and kidneys, but does not stop their progression toward it.

Comments 0 comments - Jul 9, 2010 - * * * * *

U.K. Study Links Metformin to B-12 Deficiency

If you take metformin to control your type 2 diabetes, ask your doctor to take a look at your vitamin B-12 levels when you get a chance. A recent British study shows that metformin may cause a deficiency in the vitamin, which is necessary for the regeneration of red blood cells and the maintenance of nervous system health.

Comments 0 comments - Jun 5, 2010 - * * * * *

Health Literacy and Safety Risks

People with diabetes who have limited health literacy are at higher risk for hypoglycemia or low blood sugar, according to a new study from researchers at the University of California, San Francisco and the Kaiser Permanente Division of Research in Oakland, CA.

Comments 0 comments - May 20, 2010 - * * * * *

U.S. Senate Report Says Glaxo Knew that Avandia Increases Risk of Heart Attacks

A U.S. Senate Finance Committee report released on February 20 says that Avandia, GlaxoSmithKline's drug for type 2 diabetes, may have caused as many as 83,000 heart attacks between 1999, when the drug was introduced, and 2007. The Senate report, culminating a two-year inquiry into the drug, also says that Glaxo knew about the drug's potential risks years before suspicions began to form regarding a connection between Avandia and heart problems.

Comments 2 comments - Feb 22, 2010 - * * * * *

Next Page » « Previous Page
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.